Table 1 Immune-related adverse events in melanoma patients <65 and >65 treated with nivolumab.
From: Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma
irAE | Incidence (%) Age <65 | Incidence (%) Age≥65 | p-value |
|---|---|---|---|
Rash | 38.5 | 40.4 | 0.966 |
Diarrhea | 30.2 | 21.2 | 0.322 |
Vitilligo | 10.4 | 7.7 | 0.805 |
Hypothyroidism | 8.3 | 5.8 | 0.811 |
Muscositis | 5.2 | 5.8 | 0.99 |
Myalgias | 4.2 | 0 | 0.336 |
Pneumonitis | 1.1 | 1.9 | 0.99 |